最初接受全身卡铂治疗的儿童中出现新的视网膜母细胞瘤肿瘤形成。

New retinoblastoma tumor formation in children initially treated with systemic carboplatin.

作者信息

Lee Thomas C, Hayashi Naomi I, Dunkel Ira J, Beaverson Katherine, Novetsky Danielle, Abramson David H

机构信息

Department of Ophthalmology, New York-Presbyterian Hospital-Weill Medical College of Cornell University, 70 East 66th Street, New York, NY 10021, USA.

出版信息

Ophthalmology. 2003 Oct;110(10):1989-94; discussion 1994-5. doi: 10.1016/S0161-6420(03)00669-9.

DOI:10.1016/S0161-6420(03)00669-9

PMID:14522776

Abstract

PURPOSE

To determine the frequency and timing of new intraocular tumor formation in children with hereditary retinoblastoma initially treated with systemic carboplatin.

DESIGN

Retrospective, noncomparative case series.

PARTICIPANTS

This study included 34 children (57 eyes) with hereditary bilateral retinoblastoma initially treated with systemic carboplatin at the Robert M. Ellsworth Ophthalmic Oncology Center at NewYork-Presbyterian Hospital from 1994 through 2000.

MAIN OUTCOME MEASURES

New tumor formation after initial treatment with systemic carboplatin.

RESULTS

There were a total of 165 tumors in 57 eyes. There were 63 new tumors in 27 eyes (47%) after administration of systemic carboplatin, for a mean of 1.1 new tumors per eye. The mean patient age at time of new tumor presentation was 9 months, with 57% of new tumors developing within 4 months of carboplatin treatment. Kaplan-Meier analysis showed that children who were treated when younger than 6 months of age were more likely to have new tumors (60%) compared with those treated after 6 months of age (31%; P = 0.0182).

CONCLUSIONS

New intraocular tumors continue to develop after systemic carboplatin; most new tumors appeared within 4 months of treatment.

摘要

目的

确定最初接受全身卡铂治疗的遗传性视网膜母细胞瘤患儿新的眼内肿瘤形成的频率和时间。

设计

回顾性、非对照病例系列研究。

参与者

本研究纳入了1994年至2000年在纽约长老会医院罗伯特·M·埃尔斯沃思眼科肿瘤中心最初接受全身卡铂治疗的34例遗传性双侧视网膜母细胞瘤患儿（57只眼）。

主要观察指标

全身卡铂初始治疗后的新肿瘤形成情况。

结果

57只眼中共有165个肿瘤。全身卡铂给药后，27只眼（47%）出现63个新肿瘤，平均每只眼有1.1个新肿瘤。新肿瘤出现时患者的平均年龄为9个月，57%的新肿瘤在卡铂治疗后4个月内发生。Kaplan-Meier分析显示，6个月龄以下接受治疗的儿童比6个月龄后接受治疗的儿童更易出现新肿瘤（60%对31%；P = 0.0182）。